Thelansis

Otoferlin Gene-Mediated Hearing Loss Market Outlook Thelansis’s “Otoferlin Gene-Mediated Hearing Loss Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Otoferlin Gene-Mediated Hearing Loss treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient share? Which events will have the grea...

 Hearing loss is a common congenital sensory disorder, affecting 1 in 500 newborns with bilateral hearing impairment. Around 50% to 60% of these cases have a genetic cause, with 80% attributed to autosomal recessive hearing loss. The OTOF gene, which encodes otoferlin, is a prominent contributor to non-syndromic recessive sensorineural hearing loss. OTOF-related deafness has two distinct forms: prelingual non-syndromic auditory neuropathy spectrum disorder (ANSD) and temperature-sensitive auditory neuropathy spectrum disorder (TS-ANSD). OTOF-related ANSD is characterized by severe-to-profound bilateral deafness from birth without inner-ear anomalies visible on MRI or CT scans of the temporal bones. Otoacoustic emissions (OAEs) are present, but auditory brain stem response is abnormal at birth. Newborn hearing screenings relying on OAEs alone may miss this condition in most cases, as OAEs can decrease or disappear with age in 20%-80% of individuals. TS-ANSD typically presents with m...

 Hearing loss is one of the most frequent congenital sensory disorders, affecting one out of every 500 newborns having bilateral hearing loss. It is reported that 50% - 60% of these cases show a genetic etiology, with 80% demonstrating autosomal recessive hearing loss. The OTOF gene, encoding otoferlin, is reported to be one of the frequent causes of non-syndromic recessive sensorineural hearing loss. Thelansis’s “Otoferlin Gene-Mediated Hearing Loss Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Otoferlin Gene-Mediated Hearing Loss treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). KOLs insights of Otoferlin Gene-Mediated Hearin...